Current Roles

Employees:
7
Revenue:
$542.5k
About
NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi. To address these rare disorders, which are also referred to as RASopathies because they are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, we are developing first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments.
NFlection Therapeutics Address
714 Woodcrest Roa
Boston, MA
United States
NFlection Therapeutics Email

Past Companies

NFlection TherapeuticsChief Operating Officer
PellePharm, a bridgebio company (Acquired by Sol-Gel)Senior Vice President, Head of Operations
DepomedSenior Vice President, Technical Operations